Over the forecast period, the Asia Pacific vascular access device market will grow moderately through 2030, driven by an expanding patient population and increasing adoption of premium-priced devices. Importantly, vascular access devices represent a key component of care for COVID-19 patients, and therefore the pandemic\u2019s impact on procedure volumes, unit sales, and revenues has been incorporated into market projections.<\/p>\n
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for vascular access devices in the Asia Pacific countries across an 11-year period.<\/p>\n
The COVID-19 global pandemic has had a dual effect on the vascular access market in the short term.<\/strong><\/p>\n How have trends in vascular access device segments changed due to COVID-19?<\/p>\n What factors contribute to these market changes?<\/p>\n What plans are being executed by manufacturers in response to the pandemic?<\/p>\n How soon will procedure volumes, sales, and revenues recover to pre-pandemic levels?<\/p>\n Despite increasing failure rates and complications requiring reinsertion, short PIVC insertions continue to be one of the most common invasive procedures in the region.<\/strong><\/p>\n What are the current clinical recommendations to reduce PIVC failure?<\/p>\n What are some of the measures taken by companies to improve PIVC insertion outcomes?<\/p>\n How will initiatives to educate nurses on PIVC insertion impact the unit sales of short PIVC?<\/p>\n Many competitors\u2019\u00a0products are entering the vascular access device market in Asia Pacific.<\/strong><\/p>\n How will new products launches impact the vascular access device market?<\/p>\n What challenges will new companies encounter in this space? Will they capture significant share from existing competitors?<\/p>\n Increasing incidence of CLABSI with CVC is resulting in a shift toward PICCs. <\/strong><\/p>\n How is the rising adoption of PICCs impacting the sales of CVC units? How does this vary across the Asia Pacific countries?<\/p>\n What are the marketing strategies adopted by companies to promote PICC sales?<\/p>\n What are some of the clinical practices initiated to reduce CLABSI with CVCs? How will this impact the CVC market?<\/p>\n How will the markets for tunneled CVCs and antimicrobial devices perform through 2030?<\/p>\n Home care therapy continues to grow in most Asia Pacific countries.<\/strong><\/p>\n What are some of the vascular access device markets likely to be impacted by the increasing adoption of home care therapy?<\/p>\n","protected":false},"template":"","class_list":["post-547711","report","type-report","status-publish","hentry","report-gateway-medtech","medtech-therapy-area-vascular-access-devices","medtech-geography-asia-pacific","medtech-date-945"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/547711","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/547711\/revisions"}],"predecessor-version":[{"id":547952,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/547711\/revisions\/547952"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=547711"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}